Lv41
670 积分 2021-12-17 加入
Erlotinib as adjuvant therapy in EGFR-mutant NSCLC
5天前
已完结
Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
5天前
已完结
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non–Small-Cell Lung Cancer: Final Results From SWOG S1403
27天前
已完结
Rank Analysis of Covariance
2个月前
已完结
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non–Small-Cell Lung Cancer: Final Results of a Phase III Trial
2个月前
已完结
Cisplatin and Oxaliplatin, but Not Carboplatin and Nedaplatin, Are Substrates for Human Organic Cation Transporters (SLC22A1–3 and Multidrug and Toxin Extrusion Family)
2个月前
已完结
Red Blood Cell Transfusion
3个月前
已完结
Combination Therapy and Appropriate Dosing to Target KRAS in Colorectal Cancer
4个月前
已完结
The 2023 AABB international guidelines for red blood cell transfusions: What is new?
5个月前
已完结
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
5个月前
已完结
皖公网安备34019202002308
